FDA Considering "Numerous" Ephedra Adverse Events In Rulemaking
This article was originally published in The Tan Sheet
FDA will take the "numerous adverse events" related to ephedra that continue to be reported to the agency into consideration as it develops rulemaking on the substance, FDA Commissioner Jane Henney, MD, said at a budget hearing of the House Agriculture Appropriations subcommittee Feb. 23.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC